Is the demand seriously that companies provide everything potentially relevant coming from their clinical trials? Or, to be cynical, is the requested change to process limited to trial outcomes supporting efforts to secure price reductions?
Latest Video
New Stories
-
Queensland to host AusBiotech International Conference and sector leadership strengthened with director re-election
October 24, 2025 - - Australian Biotech -
David Henderson to Lead Takeda’s Specialty Franchise in Oceania
October 24, 2025 - - Latest News -
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 24, 2025 - - BioPharma -
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News -
Global focus intensifies as AusBiotech strengthens trade, partnerships and international engagement
October 23, 2025 - - Australian Biotech -
Queensland resources sector backs prevention-first health push to boost workforce productivity
October 23, 2025 - - Latest News -
Omico appoints Richard Vines as new Chair as it strengthens national precision oncology agenda
October 23, 2025 - - Latest News
